Wassilios Meissner
Team leader
Professor - Hospital practitioner - MD-PhD (PU PH) / Université de Bordeaux / CHU/ Contact
www.orcid.org/0000-0003-2172-7527
Scientific articles
-
Movement Disorders Society Viewpoint on Biological Frameworks of Parkinson’s Disease: Current Status and Future Directions
Movement Disorders. 2024-09-09.
10.1002/mds.30007 -
Factors associated with self-rated health in people with late-stage parkinson’s and cognitive impairment
Qual Life Res. 2024-06-18.
10.1007/s11136-024-03703-2 -
Genome sequence analyses identify novel risk loci for multiple system atrophy
Neuron. 2024-05-01.
10.1016/j.neuron.2024.04.002 -
Amantadine use in the French prospective NS-Park cohort
J Neural Transm. 2024-04-05.
10.1007/s00702-024-02772-4 -
Trial of Lixisenatide in Early Parkinson’s Disease
N Engl J Med. 2024-04-04. 390(13) : 1176-1185.
10.1056/NEJMoa2312323 -
Patient-perceived progression in multiple system atrophy: natural history of quality of life
J Neurol Neurosurg Psychiatry. 2024-03-07. : jnnp-2023-332733.
10.1136/jnnp-2023-332733 -
Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries
Movement Disorders. 2024-02-29. 39(3) : 571-584.
10.1002/mds.29718 -
Recent Advances in Clinical Trials in Multiple System Atrophy
Curr Neurol Neurosci Rep. 2024-02-28. 24(4) : 95-112.
10.1007/s11910-024-01335-0 -
Reconsidering α-Synuclein inclusion pathology in neurons, mice, and humans with an antibody sensing NAC engagement during α-Synuclein amyloid conversion
Preprint - Research Square. 2024-02-07.
10.21203/rs.3.rs-3921168/v1 -
The Care Needs of Patients With Cognitive Impairment in Late-Stage Parkinson’s Disease
J Geriatr Psychiatry Neurol. 2024-01-17.
10.1177/08919887231225484 -
Staging of progressive supranuclear palsy-Richardson syndrome using MRI brain charts for the human lifespan
Brain Communications. 2024-01-01. 6(2)
10.1093/braincomms/fcae055 -
A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson’s Disease
Movement Disorders. 2023-12-13. 39(2) : 259-266.
10.1002/mds.29683 -
Meaning in Life in Late-Stage Parkinson’s Disease: Results from the Care of Late-Stage Parkinsonism Study (CLaSP) in Six European Countries
J Relig Health. 2023-12-05. 63(3) : 2140-2154.
10.1007/s10943-023-01962-w -
Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study
Movement Disorders. 2023-11-07.
10.1002/mds.29633 -
Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study
J Neurol. 2023-08-31.
10.1007/s00415-023-11947-0 -
α-Synuclein-carrying astrocytic extracellular vesicles in Parkinson pathogenesis and diagnosis
Transl Neurodegener. 2023-08-25. 12(1)
10.1186/s40035-023-00372-y -
Disease Progression in Multiple System Atrophy: The Value of Clinical Cohorts with Long Follow‐Up
Movement Disorders. 2023-08-01. 38(8) : 1567-1569.
10.1002/mds.29534 -
Describing complex disease progression using joint latent class models for multivariate longitudinal markers and clinical endpoints
Statistics in Medicine. 2023-07-17. 42(22) : 3996-4014.
10.1002/sim.9844 -
GRK2‐ Targeted Knockdown as Therapy for Multiple System Atrophy
Movement Disorders. 2023-04-24.
10.1002/mds.29422 -
Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations
Movement Disorders. 2023-04-20. 38(6) : 1008-1026.
10.1002/mds.29392 -
UMSARS versus laryngoscopy‐based assessment of dysphagia
Movement Disord Clin Pract. 2023-03-29.
10.1002/mdc3.13734 -
Trial of Deferiprone in Parkinson’s Disease.
N Engl J Med. 2022-12-01. 387(22) : 2045-2055.
10.1056/nejmoa2209254 -
Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy
Parkinsonism & Related Disorders. 2022-10-01. 103 : 56-59.
10.1016/j.parkreldis.2022.08.026 -
Personality assessment with Temperament and Character Inventory in Parkinson’s disease
Parkinsonism & Related Disorders. 2022-10-01. 103 : 34-41.
10.1016/j.parkreldis.2022.08.004 -
A comparative study on vowel articulation in Parkinson’s disease and multiple system atrophy
Interspeech 2022. 2022-09-18.
10.21437/Interspeech.2022-845 -
The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations
Movement Disorders. 2022-09-08. 37(12) : 2336-2341.
10.1002/mds.29215 -
The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations
Movement Disorders. 2022-09-08. 37(12) : 2336-2341.
10.1002/mds.29215 -
Multiple system atrophy
Nat Rev Dis Primers. 2022-08-25. 8(1)
10.1038/s41572-022-00382-6 -
The New Zealand Parkinson’s progression programme
Journal of the Royal Society of New Zealand. 2022-08-14. : 1-23.
10.1080/03036758.2022.2111448 -
Patient‐Reported Symptoms in the Global Multiple System Atrophy Registry ( GLOMSAR )
Movement Disord Clin Pract. 2022-08-10.
10.1002/mdc3.13544 -
Neurofilament light levels predict clinical progression and death in multiple system atrophy
Brain. 2022-07-29. 145(12) : 4398-4408.
10.1093/brain/awac253 -
Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease
Brain. 2022-07-14. 146(1) : 195-208.
10.1093/brain/awac258 -
Limbic Stimulation Drives Mania in STN-DBS in Parkinson Disease: A Prospective Study
Annals of Neurology. 2022-07-12. 92(3) : 411-417.
10.1002/ana.26434 -
Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout
Methods. 2022-07-01. 203 : 142-151.
10.1016/j.ymeth.2022.03.003 -
Age and Gender Differences in Cardiovascular Autonomic Failure in the Transgenic PLP-syn Mouse, a Model of Multiple System Atrophy
Front. Neurol.. 2022-06-02. 13
10.3389/fneur.2022.874155 -
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders
Revue Neurologique. 2022-05-01.
10.1016/j.neurol.2022.03.010 -
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy
Movement Disorders. 2022-04-21.
10.1002/mds.29005 -
Tracheostomy invasive ventilation for stridor in multiple system atrophy
Parkinsonism & Related Disorders. 2022-04-01.
10.1016/j.parkreldis.2022.04.016 -
Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy
Euro J of Neurology. 2022-01-27. 29(4) : 1025-1034.
10.1111/ene.15232 -
Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson’s disease
NeuroImage: Clinical. 2022-01-01. 36 : 103231.
10.1016/j.nicl.2022.103231 -
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies
Brain. 2021-12-11. 145(2) : 584-595.
10.1093/brain/awab431 -
Neurodegenerative Traits Detected via 3D CNNs Trained with Simulated Brain MRI: Prediction Supported by Visualization of Discriminant Voxels
2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). 2021-12-09.
10.1109/BIBM52615.2021.9669894 -
An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale
Parkinsonism & Related Disorders. 2021-11-01.
10.1016/j.parkreldis.2021.11.024 -
Distortion of voiced obstruents for differential diagnosis between parkinson’s disease and multiple system atrophy
Interspeech 2021. 2021-08-30.
10.21437/Interspeech.2021-223 -
Impaired brain insulin signalling in Parkinson’s disease
Neuropathol Appl Neurobiol. 2021-08-17.
10.1111/nan.12760 -
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
JPD. 2021-08-02. 11(3) : 1079-1089.
10.3233/JPD-212594 -
Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson’s Disease
Front. Aging Neurosci.. 2021-07-26. 13
10.3389/fnagi.2021.632891 -
Why and how evaluating driving abilities in patients with neurodegenerative diseases?
Gériatrie et Psychologie Neuropsychiatrie du Viellissement. 2021-06-01. 19(2) : 191-201.
10.1684/pnv.2021.0933 -
Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment
Parkinsonism & Related Disorders. 2021-05-01. 86 : 124-132.
10.1016/j.parkreldis.2021.03.027 -
A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): Rationale, design and baseline data
. 2021-04-15.
10.1101/2021.04.09.21251911 -
Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial
Mov Disord. 2021-04-01. 36(7) : 1704-1711.
10.1002/mds.28569 -
Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review
Mov Disord. 2021-03-19. 36(7) : 1499-1510.
10.1002/mds.28517 -
Factors associated with health‐related quality of life in late stage Parkinson’s disease
Mov Disord Clin Pract. 2021-03-11.
10.1002/mdc3.13186 -
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
The Lancet Neurology. 2021-03-01. 20(3) : 182-192.
10.1016/S1474-4422(20)30489-0 -
Laboratory‐supported multiple system atrophy beyond autonomic function testing and imaging: A systematic review by the modimsa study group
Mov Disord Clin Pract. 2021-02-01.
10.1002/mdc3.13158 -
A Modified Progressive Supranuclear Palsy Rating Scale
Mov Disord. 2021-01-29. 36(5) : 1203-1215.
10.1002/mds.28470 -
The European Reference Network for Rare Neurological Diseases
Front. Neurol.. 2021-01-14. 11
10.3389/fneur.2020.616569 -
A Phase 2 Randomized Trial of Asleep versus Awake Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease
Stereotact Funct Neurosurg. 2020-11-30. 99(3) : 230-240.
10.1159/000511424 -
Insulin resistance, diabetes and Parkinson’s disease: The match continues
Parkinsonism & Related Disorders. 2020-11-01. 80 : 199-200.
10.1016/j.parkreldis.2020.10.013 -
Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy
Cells. 2020-10-29. 9(11) : 2371.
10.3390/cells9112371 -
Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease
Mov Disord. 2020-10-27. 36(2) : 449-459.
10.1002/mds.28338 -
Caregiver Burden in Late-Stage Parkinsonism and Its Associations
J Geriatr Psychiatry Neurol. 2020-10-23. : 089198872096826.
10.1177/0891988720968263 -
Correction to: Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort (Journal of Neural Transmission, (2020), 127, 12, (1607-1617), 10.1007/s00702-020-02249-0)
J Neural Transm. 2020-10-21. 128(6) : 871-872.
10.1007/s00702-020-02264-1 -
Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance
Mov Disord. 2020-09-11. 35(12) : 2301-2313.
10.1002/mds.28263 -
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
Mov Disord. 2020-09-03.
10.1002/mds.28218 -
Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort
J Neural Transm. 2020-09-02. 127(12) : 1607-1617.
10.1007/s00702-020-02249-0 -
Can autonomic testing and imaging contribute to the early diagnosis of MSA ? A systematic review and recommendations by the MDS multiple system atrophy ( MoDiMSA ) study group
Mov Disord Clin Pract. 2020-08-17.
10.1002/mdc3.13052 -
Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson’s Disease
Mov Disord. 2020-08-15. 35(11) : 2101-2106.
10.1002/mds.28192 -
Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic
BMC Med Educ. 2020-07-29. 20(1)
10.1186/s12909-020-02161-x -
Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial
JPD. 2020-07-28. 10(3) : 1171-1184.
10.3233/JPD-202033 -
Characteristics of Patients with Late-Stage Parkinsonism who are Nursing Home Residents Compared with those Living at Home
Journal of the American Medical Directors Association. 2020-07-01.
10.1016/j.jamda.2020.06.025 -
Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson’s disease patients with GBA mutations
Parkinsonism & Related Disorders. 2020-07-01. 76 : 56-62.
10.1016/j.parkreldis.2020.04.002 -
Management of rare movement disorders in Europe: outcome of surveys of the European Reference Network for Rare Neurological Diseases
Eur J Neurol. 2020-06-19.
10.1111/ene.14302 -
Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study
Neurobiology of Disease. 2020-06-01. 139 : 104813.
10.1016/j.nbd.2020.104813 -
The late stage of Parkinson’s –results of a large multinational study on motor and non-motor complications
Parkinsonism & Related Disorders. 2020-06-01. 75 : 91-96.
10.1016/j.parkreldis.2020.05.016 -
Reduced oligodendrocyte exosome secretion in multiple system atrophy involves SNARE dysfunction
Brain. 2020-05-18.
10.1093/brain/awaa110 -
Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease
Neurology. 2020-05-12. 94(21) : e2189-e2202.
10.1212/WNL.0000000000009474 -
Looking into the prediagnostic phase of progressive supranuclear palsy
Parkinsonism & Related Disorders. 2020-05-01. 74 : 74-75.
10.1016/j.parkreldis.2020.04.006 -
The prevalence and determinants of neuropsychiatric symptoms in late‐stage parkinsonism
Mov Disord Clin Pract. 2020-04-27.
10.1002/mdc3.12968 -
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy
Mov Disord. 2020-04-14.
10.1002/mds.28034 -
Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study
Drugs Aging. 2020-01-10. 37(3) : 215-223.
10.1007/s40266-019-00740-2 -
Multiple System Atrophy: Recent Developments and Future Perspectives
Mov Disord. 2019-11-06.
10.1002/mds.27894 -
Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies
Mov Disord. 2019-09-30. 35(1) : 171-176.
10.1002/mds.27872 -
Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment
Neurology. 2019-09-30. 93(14) : 630-639.
10.1212/WNL.0000000000008208 -
AETIONOMY, a cross-sectional study aimed at validating a new taxonomy of neurodegenerative diseases: Study design and subject characteristics
. 2019-09-05.
10.1101/19004804 -
A genome-wide genetic pleiotropy approach identified shared loci between multiple system atrophy and inflammatory bowel disease
. 2019-08-31.
10.1101/751354 -
Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies
JCI Insight. 2019-08-22. 4(16)
10.1172/jci.insight.129719 -
Four-repeat tauopathies.
Progress in Neurobiology. 2019-06-01. : 101644.
10.1016/j.pneurobio.2019.101644 -
Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease
J Neural Transm. 2019-05-16. 126(6) : 789-793.
10.1007/s00702-019-02015-x -
A critique of the second consensus criteria for multiple system atrophy.
Mov Disord. 2019-04-29.
10.1002/mds.27701 -
Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson’s disease cohort?
Parkinsonism & Related Disorders. 2019-04-01.
10.1016/j.parkreldis.2019.04.012 -
How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.
Mov Disord. 2019-03-18.
10.1002/mds.27666 -
Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type.
Parkinsonism & Related Disorders. 2019-02-01.
10.1016/j.parkreldis.2019.02.006 -
Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
J. Clin. Psychiatry. 2019-01-08. 80(1)
10.4088/jcp.18m12246 -
A totally data-driven whole-brain multimodal pipeline for the discrimination of Parkinson’s disease, multiple system atrophy and healthy control.
NeuroImage: Clinical. 2019-01-01. 23 : 101858.
10.1016/j.nicl.2019.101858 -
LRP10 in α-synucleinopathies
The Lancet Neurology. 2018-12-01. 17(12) : 1033-1034.
10.1016/S1474-4422(18)30407-1 -
Factors associated with spousal burden in Parkinson’s disease
Revue Neurologique. 2018-12-01. 174(10) : 711-715.
10.1016/j.neurol.2018.01.372 -
Multiple system atrophy | L’atrophie multisystématisée
. .
10.1684/pnv.2010.0212 -
Case Study 7
Parkinsonian Disorders in Clinical Practice. . : 63-192.
10.1002/9781444306385.ch3 -
Etiological assessment of cerebral infarcts in young subjects. Propositions of the French Neurovascular Society Working Group (December 2008) | Bilan étiologique des infarctus cérébraux du sujet jeune. Propositions du Groupe de travail de la Société française neuro-vasculaire (décembre 2008)
. .
RN-12-2009-165-HS4-0035-3787-101019-200908769 -
Study protocol: Care of Late-Stage Parkinsonism (CLaSP): A longitudinal cohort study
BMC Neurol. 2018-11-05. 18(1)
10.1186/s12883-018-1184-3 -
Study protocol: Care of Late-Stage Parkinsonism (CLaSP): A longitudinal cohort study 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1109 Neurosciences
BMC Neurol. 2018-11-05. 18(1)
10.1186/s12883-018-1184-3 -
Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study
Parkinsonism & Related Disorders. 2018-11-01. 56 : 33-40.
10.1016/j.parkreldis.2018.06.015 -
Deep brain stimulation does not enhance neuroinflammation in multiple system atrophy
Neurobiology of Disease. 2018-10-01. 118 : 155-160.
10.1016/j.nbd.2018.07.016 -
Naftazone in advanced Parkinson’s disease: An acute L-DOPA challenge randomized controlled trial
Parkinsonism & Related Disorders. 2018-10-01.
10.1016/j.parkreldis.2018.10.005 -
Lysosomal storage disorder gene variants in multiple system atrophy
Brain. 2018-05-07. 141(7) : e53-e53.
10.1093/brain/awy124 -
Present and future of disease-modifying therapies in multiple system atrophy.
Autonomic Neuroscience. 2018-05-01. 211 : 31-38.
10.1016/j.autneu.2017.12.008 -
Targeting alpha-synuclein for treating Parkinson’s disease and other synucleinopathies,Stratégies thérapeutiques ciblant l’alpha-synucléine pour le traitement de la maladie de Parkinson et des autres synucléinopathies
Pratique Neurologique - FMC. 2018-04-01. 9(2) : 156-161.
10.1016/j.praneu.2018.02.005 -
MRI supervised and unsupervised classification of Parkinson’s disease and multiple system atrophy
Mov Disord.. 2018-02-23. 33(4) : 600-608.
10.1002/mds.27307 -
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting
Neurology. 2017-12-13. 90(2) : 74-82.
10.1212/WNL.0000000000004798 -
L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.
Eur J Neurol. 2017-10-09. 24(12) : 1532-1538.
10.1111/ene.13466 -
Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.
Mov Disord.. 2017-05-29. 32(8) : 1230-1239.
10.1002/mds.27041 -
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Mov Disord.. 2017-05-13. 32(7) : 995-1005.
10.1002/mds.27034 -
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Mov Disord.. 2017-05-03. 32(6) : 853-864.
10.1002/mds.26987 -
Multiple System Atrophy – State of the Art.
Curr Neurol Neurosci Rep. 2017-04-04. 17(5)
10.1007/s11910-017-0751-0 -
Insulin resistance and exendin-4 treatment for multiple system atrophy.
Brain. 2017-03-14. 140(5) : 1420-1436.
10.1093/brain/awx044 -
Epidemiology, environmental risk factors and genetics of Parkinson’s disease | Épidémiologie, facteurs de risque environnementaux et génétiques de la maladie de Parkinson
La Presse Médicale. 2017-03-01. 46(2) : 175-181.
10.1016/j.lpm.2017.01.001 -
Impact of sleep apnea syndrome on survival in patients with multiple system atrophy.
Parkinsonism & Related Disorders. 2017-02-01. 35 : 92-95.
10.1016/j.parkreldis.2016.12.013 -
Exosomes, an Unmasked Culprit in Neurodegenerative Diseases.
Front. Neurosci.. 2017-01-31. 11
10.3389/fnins.2017.00026 -
The many faces of autonomic failure in multiple system atrophy
Mov Disord.. 2017-01-16. 32(3) : 368-370.
10.1002/mds.26917 -
Analysis of the prion protein gene in multiple system atrophy
Neurobiology of Aging. 2017-01-01. 49 : 216.e15-216.e18.
10.1016/j.neurobiolaging.2016.09.021 -
A genome-wide association study in multiple system atrophy
Neurology. 2016-09-14. 87(15) : 1591-1598.
10.1212/WNL.0000000000003221 -
Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.
Proc Natl Acad Sci USA. 2016-08-01. 113(34) : 9593-9598.
10.1073/pnas.1609291113 -
Outcome of deep brain stimulation in slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature
Parkinsonism & Related Disorders. 2016-03-01. 24 : 69-75.
10.1016/j.parkreldis.2016.01.005 -
Targeting α-synuclein: Therapeutic options.
Mov Disord.. 2016-03-01. 31(6) : 882-888.
10.1002/mds.26568 -
Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease
Mov Disord.. 2015-12-17. 31(3) : 325-334.
10.1002/mds.26471 -
Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson’s disease dementia
Parkinsonism & Related Disorders. 2015-10-01. 21(10) : 1273-1277.
10.1016/j.parkreldis.2015.08.013 -
Delayed-onset Friedreich’s ataxia revisited
Mov Disord.. 2015-09-21. 31(1) : 62-69.
10.1002/mds.26382 -
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease.
Progress in Neurobiology. 2015-09-01. 132 : 96-168.
10.1016/j.pneurobio.2015.07.002 -
Region-Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy
Mov Disord.. 2015-08-11. 30(13) : 1802-1812.
10.1002/mds.26329 -
Targeting α-synuclein for treatment of Parkinson’s disease: Mechanistic and therapeutic considerations
The Lancet Neurology. 2015-08-01. 14(8) : 855-866.
10.1016/S1474-4422(15)00006-X -
Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative
Neurobiology of Disease. 2015-08-01. 80 : 29-41.
10.1016/j.nbd.2015.05.004 -
New insights into orthostatic hypotension in multiple system atrophy: A European multicentre cohort study
J Neurol Neurosurg Psychiatry. 2015-05-14. 87(5) : 554-561.
10.1136/jnnp-2014-309999 -
Falls in ambulatory non-demented patients with Parkinson’s disease
J Neural Transm. 2015-04-07. 122(10) : 1447-1455.
10.1007/s00702-015-1396-2 -
Multiple system atrophy | L’atrophie multisystématisée
Pratique Neurologique - FMC. 2015-03-01. 6(2) : 115-123.
10.1016/j.praneu.2014.12.003 -
Current Concepts in the Treatment of Multiple System Atrophy
Mov Disord Clin Pract. 2015-02-02. 2(1) : 6-16.
10.1002/mdc3.12145 -
Presumed tuberculous retrobulbar optic neuritis: a diagnosis challenge
J Neurol. 2014-12-24. 262(2) : 481-484.
10.1007/s00415-014-7611-5 -
Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice
J Neurol. 2014-12-02. 262(2) : 435-442.
10.1007/s00415-014-7557-7 -
Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease
J Crohns Colitis. 2014-09-01. 8(9) : 1138-1139.
10.1016/j.crohns.2014.02.004 -
Mutant COQ2 in multiple-system atrophy.
N Engl J Med. 2014-07-03. 371(1) : 80-83.
10.1056/NEJMc1311763#SA3 -
Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
JAMA Neurol. 2014-07-01. 71(7) : 884.
10.1001/jamaneurol.2014.753 -
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?
Progress in Neurobiology. 2014-07-01. 118 : 1-18.
10.1016/j.pneurobio.2014.02.005 -
Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies.
Neurobiology of Disease. 2014-07-01. 67 : 133-139.
10.1016/j.nbd.2014.03.021 -
Coordinated reset neuromodulation for Parkinson’s disease: Proof-of-concept study
Mov Disord.. 2014-06-28. 29(13) : 1679-1684.
10.1002/mds.25923 -
Coordinated reset neuromodulation for Parkinson’s disease: Proof-of-concept study.
Mov Disord.. 2014-06-28. 29(13) : 1679-1684.
10.1002/mds.25923 -
Restless legs syndrome in multiple system atrophy.
J Neural Transm. 2014-05-13. 121(12) : 1523-1527.
10.1007/s00702-014-1232-0 -
Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.
Mov Disord.. 2014-04-18. 29(7) : 857-867.
10.1002/mds.25880 -
Accuracy of portable polygraphy for the diagnosis of sleep apnea in multiple system atrophy.
Sleep Medicine. 2014-04-01. 15(4) : 476-479.
10.1016/j.sleep.2013.12.013 -
A cross-sectional study on drug use in multiple system atrophy
CNS Drugs. 2014-03-29. 28(5) : 483-490.
10.1007/s40263-014-0159-1 -
Intra-axonal protein aggregation in the peripheral nervous system.
J Peripher Nerv Syst. 2014-03-01. 19(1) : 44-49.
10.1111/jns5.12056 -
Breathing variability and brainstem serotonergic loss in a genetic model of multiple system atrophy.
Mov Disord.. 2014-01-17. 29(3) : 388-395.
10.1002/mds.25804 -
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Sci Rep. 2014-01-16. 4(1)
10.1038/srep03730 -
Movement disorders in 2013: Diagnosing and treating PD-the earlier the better?
Nat Rev Neurol. 2014-01-07. 10(2) : 65-66.
10.1038/nrneurol.2013.273 -
Withdrawing amantadine in dyskinetic patients with Parkinson disease : The AMANDYSK trial
Neurology. 2013-12-26. 82(4) : 300-307.
10.1212/WNL.0000000000000050 -
Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease
Neurology: Clinical Practice. 2013-12-01. 3(6) : 480-481.
10.1212/01.CPJ.0000437017.29917.c9 -
Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy
Synapse. 2013-11-15. 68(3) : 98-106.
10.1002/syn.21719 -
Facial emotion recognition is inversely correlated with tremor severity in essential tremor
J Neural Transm. 2013-11-01. 121(4) : 347-351.
10.1007/s00702-013-1110-1 -
Isolated generalized dystonia in biallelic missense mutations of the ATM gene
Mov Disord.. 2013-05-02. 28(13) : 1897-1899.
10.1002/mds.25487 -
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients.
Parkinsonism & Related Disorders. 2013-04-01. 19(4) : 416-421.
10.1016/j.parkreldis.2012.12.003 -
The natural history of multiple system atrophy: A prospective European cohort study
The Lancet Neurology. 2013-03-01. 12(3) : 264-274.
10.1016/S1474-4422(12)70327-7 -
Validation of the French version of the MSA health-related Quality of Life scale (MSA-QoL)
Revue Neurologique. 2013-01-01. 169(1) : 53-58.
10.1016/j.neurol.2012.02.011 -
Coordinated reset has sustained aftereffects in Parkinsonian monkeys.
Ann Neurol.. 2012-11-01. 72(5) : 816-820.
10.1002/ana.23663 -
When does Parkinson’s disease begin? from prodromal disease to motor signs
Revue Neurologique. 2012-11-01. 168(11) : 809-814.
10.1016/j.neurol.2012.07.004 -
New insights and the need for revised diagnostic criteria
Neurology. 2012-10-17. 79(18) : 1898-1907.
10.1212/WNL.0b013e318271f7ff -
Assessment of quality of life with the multiple system atrophy health-related quality of life scale
Mov. Disord.. 2012-10-01. 27(12) : 1574-1577.
10.1002/mds.25174 -
Methods for treating neurological conditions (WO2011159945)
Expert Opinion on Therapeutic Patents. 2012-06-15. 22(7) : 847-852.
10.1517/13543776.2012.699524 -
Assessment of the Scopa-Aut questionnaire in multiple system atrophy: Relation to UMSARS scores and progression over time
Parkinsonism & Related Disorders. 2012-06-01. 18(5) : 612-615.
10.1016/j.parkreldis.2011.12.009 -
A long-term follow-up of weight changes in subthalamic nucleus stimulated Parkinson’s disease patients
Revue Neurologique. 2012-02-01. 168(2) : 173-176.
10.1016/j.neurol.2011.04.006 -
Ambiguous mechanisms of dysphagia in multiple system atrophy
Brain. 2011-08-08. 135(2) : e205-e205.
10.1093/brain/awr185 -
The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research
2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. 2011-08-01.
10.1109/IEMBS.2011.6090148 -
Development of an implantable microstimulation system for chronic DBS in rodents
2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. 2011-08-01.
10.1109/IEMBS.2011.6090147 -
Subthalamic deep brain stimulation increases pallidal firing rate and regularity
Experimental Neurology. 2011-06-01. 229(2) : 517-521.
10.1016/j.expneurol.2011.01.020 -
Priorities in Parkinson’s disease research.
Nat Rev Drug Discov. 2011-05-01. 10(5) : 377-393.
10.1038/nrd3430 -
Acquired hepatocerebral degeneration
Handbook of Clinical Neurology. 2011-01-01. : 193-197.
10.1016/B978-0-444-52014-2.00011-2 -
L-dopa-induced dyskinesia-clinical presentation, genetics, and treatment
International Review of Neurobiology. 2011-01-01. : 31-54.
10.1016/B978-0-12-381328-2.00002-X -
Normal cerebrovascular reactivity in stroke-like migraine attacks after radiation therapy syndrome
Clinical Nuclear Medicine. 2010-08-01. 35(8) : 583-585.
10.1097/RLU.0b013e3181e4db6f -
Dyspnea as first sign of autonomic failure in postmortem confirmed multiple system atrophy
Mov. Disord.. 2010-07-28. 25(12) : 1997-1998.
10.1002/mds.23182 -
Multiple system atrophy: Current and future approaches to management
Ther Adv Neurol Disord. 2010-06-23. 3(4) : 249-263.
10.1177/1756285610375328 -
Deep brain stimulation changes basal ganglia output nuclei firing pattern in the dystonic hamster
Neurobiology of Disease. 2010-05-01. 38(2) : 288-298.
10.1016/j.nbd.2010.01.020 -
Opsoclonus myoclonus syndrome in the context of Salmonellosis
Mov Disord.. 2009-11-15. 24(15) : 2306-2308.
10.1002/mds.22832 -
High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster.
Neurobiology of Disease. 2009-09-01. 35(3) : 399-405.
10.1016/j.nbd.2009.05.022 -
Axonal sensory motor neuropathy in copper-deficient wilson’s disease
Muscle Nerve. 2009-08-01. 40(2) : 294-296.
10.1002/mus.21425 -
Use of the Triage Stroke Panel in a neurologic emergency service
The American Journal of Emergency Medicine. 2009-06-01. 27(5) : 558-562.
10.1016/j.ajem.2008.05.001 -
Dopamine transporter binding is reduced following disulfiram-induced striatal damage
Mov Disord.. 2009-04-30. 24(6) : 941-943.
10.1002/mds.22397 -
Hearing and seeing: Unusual early signs of Wernicke encephalopathy
Neurology. 2008-08-25. 71(9) : 694-694.
10.1212/01.wnl.0000324599.66359.b1 -
Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats.
Neuroscience. 2008-06-01. 153(4) : 1213-1224.
10.1016/j.neuroscience.2008.01.084 -
Deep-brain stimulation of the internal pallidum in multiple system atrophy | Stimulation cérébrale profonde du pallidum interne dans l’atrophie multisystématisée
Revue Neurologique. 2008-04-01. 164(4) : 398-402.
10.1016/j.neurol.2008.01.004 -
Measure of the regularity of events in stochastic point processes, application to neuron activity analysis
2008 IEEE International Conference on Acoustics, Speech and Signal Processing. 2008-03-01.
10.1109/ICASSP.2008.4517653 -
Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism
Experimental Neurology. 2008-03-01. 210(1) : 257-260.
10.1016/j.expneurol.2007.10.002 -
Subthalamic stimulation increases striatal tyrosine hydroxylase phosphorylation
NeuroReport. 2008-01-01. 19(2) : 179-182.
10.1097/WNR.0b013e3282f417b4 -
Continuous high-frequency stimulation in freely moving rats: Development of an implantable microstimulation system
Journal of Neuroscience Methods. 2008-01-01. 167(2) : 278-291.
10.1016/j.jneumeth.2007.08.019 -
High frequency stimulation of the subthalamic nucleus modulates neurotransmission in limbic brain regions of the rat
Exp Brain Res. 2007-10-26. 185(3) : 497-507.
10.1007/s00221-007-1171-1 -
Late emergence of synchronized oscillatory activity in the pallidum during progressive parkinsonism
European Journal of Neuroscience. 2007-09-14. 26(6) : 1701-1713.
10.1111/j.1460-9568.2007.05777.x -
Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson’s disease.
European Journal of Neuroscience. 2007-04-05. 25(5) : 1492-1500.
10.1111/j.1460-9568.2007.05406.x -
MRI versus CT in acute stroke
The Lancet. 2007-04-01. 369(9570) : 1342.
10.1016/S0140-6736(07)60623-0 -
Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys.
European Journal of Neuroscience. 2006-08-01. 24(4) : 1201-1208.
10.1111/j.1460-9568.2006.04984.x -
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
Neurobiology of Disease. 2006-06-01. 22(3) : 586-598.
10.1016/j.nbd.2006.01.009 -
Competition between feedback loops underlies normal and pathological dynamics in the basal ganglia
Journal of Neuroscience. 2006-03-29. 26(13) : 3567-3583.
10.1523/JNEUROSCI.5050-05.2006 -
Fatal embolic myocardial infarction after systemic thrombolysis for stroke
Cerebrovasc Dis. 2006-01-01. 22(2-3) : 213-214.
10.1159/000093812 -
Subthalamic nucleus lesioning inhibits expression and phosphorylation of c-Jun in nigral neurons in the rat’s 6-OHDA model of Parkinson’s disease
Synapse. 2006-01-01. 60(1) : 69-80.
10.1002/syn.20269 -
Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations
Brain. 2005-08-25. 128(10) : 2372-2382.
10.1093/brain/awh616 -
Dopamine depletion increases the power and coherence of β-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat
European Journal of Neuroscience. 2005-03-01. 21(5) : 1413-1422.
10.1111/j.1460-9568.2005.03973.x -
Deep brain stimulation in late stage Parkinson’s disease: A retrospective cost analysis in Germany
J Neurol. 2005-02-01. 252(2) : 218-223.
10.1007/s00415-005-0640-3 -
Coherent spike-wave oscillations in the cortex and subthalamic nucleus of the freely moving rat
Neuroscience. 2005-01-01. 132(3) : 659-664.
10.1016/j.neuroscience.2005.01.006 -
Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortex.
Neurochemistry International. 2004-12-01. 45(7) : 995-1004.
10.1016/j.neuint.2004.06.003 -
The effects of electrode material, charge density and stimulation duration on the safety of high-frequency stimulation of the subthalamic nucleus in rats
Journal of Neuroscience Methods. 2004-09-01. 138(1-2) : 207-216.
10.1016/j.jneumeth.2004.04.019 -
High-frequency stimulation of the entopeduncular nucleus improves dystonia in dtsz hamsters
NeuroReport. 2004-06-01. 15(9) : 1391-1393.
10.1097/01.wnr.0000130435.75715.64 -
Subthalamic high frequency stimulation induced rotations are differentially mediated by D1 and D2 receptors
Neuropharmacology. 2004-06-01. 46(7) : 974-983.
10.1016/j.neuropharm.2004.01.007 -
Neuroprotective strategies for Parkinson’s disease: conceptual limits of animal models and clinical trials.
Trends in Pharmacological Sciences. 2004-05-01. 25(5) : 249-253.
10.1016/j.tips.2004.03.003 -
High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism.
The FASEB Journal. 2004-03-01. 18(3) : 528-530.
10.1096/fj.03-0576fje -
High frequency stimulation of the entopeduncular nucleus has no effect on striatal dopaminergic transmission
Neurochemistry International. 2004-03-01. 44(4) : 281-286.
10.1016/S0197-0186(03)00138-4 -
Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson’s disease
Experimental Neurology. 2004-02-01. 185(2) : 272-280.
10.1016/S0014-4886(03)00363-7 -
Deep brain stimulation in dystonia
Journal of Neurology. 2003-10-01. 250(10) : 1201-1205.
10.1007/s00415-003-0179-0 -
The effects of frequency in pallidal deep brain stimulation for primary dystonia
Journal of Neurology. 2003-10-01. 250(10) : 1201-1205.
10.1007/s00415-003-0179-0 -
Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei
Neurobiology of Disease. 2003-06-01. 13(1) : 46-54.
10.1016/S0969-9961(03)00011-1 -
The deafferented nonhuman primate is not a reliable model of intractable pain.
Neurological Research. 2003-03-01. 25(2) : 127-129.
10.1179/016164103101201274 -
Time-Course of Nigrostriatal Degeneration in a Progressive MPTP-Lesioned Macaque Model of Parkinson’s Disease
MN. 2003-01-01. 28(3) : 209-218.
10.1385/MN:28:3:209 -
Oscillatory local field potentials recorded from the subthalamic nucleus of the alert rat
Experimental Neurology. 2002-10-01. 177(2) : 581-585.
10.1006/exnr.2002.7984 -
Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats
Neuroscience Letters. 2002-08-01. 328(2) : 105-108.
10.1016/S0304-3940(02)00463-9 -
Apomorphine versus deep-brain stimulation: Clinical and economic aspects in late-stage Parkinson’s disease | Apomorphintherapie versus tiefe hirnstimulation: Klinische und ökonomische aspekte bei patienten mit fortgeschrittenem morbus Parkinson
Der Nervenarzt. 2001-12-01. 72(12) : 924-927.
10.1007/s001150170004 -
Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats
Neuroscience Letters. 2001-05-01. 303(3) : 165-168.
10.1016/S0304-3940(01)01758-X -
Pallidal and thalamic neurostimulation in severe tardive dystonia
Journal of Neurology, Neurosurgery & Psychiatry. 2001-04-01. 70(4) : 557-559.
10.1136/jnnp.70.4.557 -
Hepatic artery resistance as a marker for preservation/reperfusion injury.
Transplantation Proceedings. 2001-02-01. 33(1-2) : 959-961.
10.1016/s0041-1345(00)02285-5 -
Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome
Mov Disord.. 2001-01-01. 16(4) : 769-771.
10.1002/mds.1119 -
Erratum: Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome (Movement Disorders (2001) vol. 16 (769-771))
Mov Disord.. 2001-01-01. 16(6) : 1204-1204.
10.1002/mds.1266 -
The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat
Neuroscience Letters. 2000-12-01. 296(2-3) : 149-152.
10.1016/S0304-3940(00)01659-1 -
Multiple lesions originating from the ventricular wall
Journal of Neurology, Neurosurgery & Psychiatry. 2000-08-01. 69(2) : 273-273.
10.1136/jnnp.69.2.273 -
Reversible leucopenia related to olanzapine
Mov. Disord.. 1999-09-01. 14(5) : 872-873.
10.1002/1531-8257(199909)14:5<872::AID-MDS1026>3.0.CO;2-Y